Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00283803 | Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer | completed | Phase 2 | 32 | University of WashingtonOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT00039624 | Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Aug 2, 2018 | clinicaltrials |
| NCT01656304 | Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 16 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 31, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00520481 | Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer | completed | Phase 2 | 41 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 19, 2018 | clinicaltrials |
| NCT01045109 | Vitamin D3 Supplementation in Participants Diagnosed With Early-Stage Prostate Cancer Who Decide to Undergo Active Surveillance Treatment Regimen.(D3/PCa) | completed | Phase 2 | 52 | Medical University of South CarolinaOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01054079 | Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00272038 | Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer | completed | Phase 2 | 29 | Oncology Specialists, S.C.OTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT00165399 | Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment | completed | Phase 2 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 25, 2018 | clinicaltrials |
| NCT00090545 | A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2018 | clinicaltrials |
| NCT01220973 | Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer | completed | Phase 2 | 27 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT01521949 | Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA | completed | Phase 2 | 21 | University of Colorado, DenverOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01620593 | Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer | completed | Phase 2 | 41 | The University of Texas Health Science Center at San AntonioOTHER | 1 | May 23, 2018 | clinicaltrials |
| NCT01090765 | A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | May 22, 2018 | clinicaltrials |
| NCT00006101 | Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer | completed | Phase 2 | 76 | Thomas E. AhleringOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT02083185 | A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer | completed | Phase 2 | 136 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | May 9, 2018 | clinicaltrials |
| NCT02130700 | Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer | completed | Phase 2 | 17 | Innocrin PharmaceuticalINDUSTRY | 1 | May 7, 2018 | clinicaltrials |
| NCT00513071 | AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 19, 2018 | clinicaltrials |
| NCT01666314 | Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 137 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 20, 2018 | clinicaltrials |
| NCT02488070 | 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer | completed | Phase 1 / Phase 2 | 10 | Stanford UniversityOTHER | 1 | Mar 20, 2018 | clinicaltrials |
| NCT00888654 | Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy | completed | Phase 2 | 41 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT01393730 | Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer | completed | Phase 2 | 40 | Mary-Ellen Taplin, MDOTHER | 1 | Mar 15, 2018 | clinicaltrials |
| NCT01496131 | Tecemotide (L-BLP25) in Prostate Cancer | completed | Phase 2 | 28 | EMD SeronoINDUSTRY | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01585428 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2018 | clinicaltrials |
| NCT02796807 | Correlation Between SUV on 68Ga-HBED-CC-PSMA and Gleason Score in Prostate Cancer | completed | Phase 2 | 88 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Mar 6, 2018 | clinicaltrials |
| NCT02958787 | Vessel Sparing Prostate Radiation Therapy | completed | Phase 2 | 135 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01120236 | Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | completed | Phase 2 | 211 | National Cancer Institute (NCI)NIH | 2 | Feb 26, 2018 | clinicaltrials |
| NCT00744549 | Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Feb 14, 2018 | clinicaltrials |
| NCT01289067 | Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca | completed | Phase 2 | 13 | William K. OhOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT00878436 | Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration | completed | Phase 1 / Phase 2 | 52 | NYU Langone HealthOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT02097303 | Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis(eRADicAte) | completed | Phase 2 | 36 | Carolina Research Professionals, LLCOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT00983710 | Prostate Cancer Symptom Management for Low Literacy Men | completed | Phase 2 | 108 | Baylor College of MedicineOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01105338 | Lycopene or Green Tea for Men at Risk of Prostate Cancer(ProDiet) | completed | Phase 2 / Phase 3 | 126 | University of BristolOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00814788 | Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer(UCDCC#215) | completed | Phase 2 | 24 | University of California, DavisOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01433913 | Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01199146 | Abiraterone Post Ketoconazole for Prostate Cancer | completed | Phase 2 | 42 | University of California, San FranciscoOTHER | 1 | Jan 8, 2018 | clinicaltrials |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | completed | Phase 2 | 63 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT00630344 | RAD001 and Bicalutamide for Androgen Independent Prostate Cancer | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT00307294 | Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC) | completed | Phase 2 | 40 | University of PittsburghOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT00466752 | Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer | completed | Phase 2 | 5 | University of WashingtonOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00331344 | Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy | completed | Phase 1 / Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2017 | clinicaltrials |
| NCT00844792 | Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer | completed | Phase 2 | 48 | University Health Network, TorontoOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT01992042 | Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer | completed | Phase 2 | 33 | University Health Network, TorontoOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT01288534 | Hypofractionated Stereotactic Body Radiation Therapy (SBRT) | completed | Phase 2 | 68 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT01756638 | A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer | completed | Phase 2 | 48 | Janssen Research & Development, LLCINDUSTRY | 1 | Oct 23, 2017 | clinicaltrials |
| NCT00887458 | A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy | completed | Phase 2 | 46 | Johns Hopkins UniversityOTHER | 1 | Oct 16, 2017 | clinicaltrials |
| NCT00953225 | Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer(vit D & PCa) | completed | Phase 2 | 83 | VA Office of Research and DevelopmentFED | 1 | Oct 9, 2017 | clinicaltrials |
| NCT00589472 | Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer(TARGET) | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2017 | clinicaltrials |
| NCT00195039 | Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer | completed | Phase 2 | 47 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 5, 2017 | clinicaltrials |
| NCT03297385 | Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation(DARANA) | completed | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 0 | Sep 29, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Aug 7, 2018source: clinicaltrials